EU funding for research into Alzheimer’s and prioniopathies
A project involving IBEC through its affiliation with CIBERNED has been approved by the EU for funding.
A project involving IBEC through its affiliation with CIBERNED has been approved by the EU for funding.
IBEC’s Nanoscale Bioelectrical Characterization group, headed by Gabriel Gomila, is a partner in a new EU-funded collaborative project set to develop a new tool for non-destructive 3D nanoscale structural characterization, the Volumetric Scanning Microwave Microscope (VSMM).
In their bulletin for February, the Spanish Association of Biotechnology Companies (ASEBIO) published an editorial by the president of their scientific committee Emilio Muñoz, about the impact of bionanotechnology in Spain and guidelines for the future.
Researchers at IBEC have made an important leap towards understanding the second most common neurodegenerative illness, Parkinson’s disease (PD), which affects around 5% of the population by age 85.Previously, it wasn’t clear whether induced pluripotent stem cells (iPSCs) – adult cells genetically reprogrammed to an embryonic stem cell-like state, which offer an unrivalled opportunity to understand many human diseases – were able to shed any light on illnesses which are age-related.
Now, a new scientific project involving IBEC and three other European research centres is set to offer a novel, minimally-invasive treatment for atherosclerosis patients, thanks to funding awarded by the European Commission.
IBEC’s Robotics group leader Alícia Casals is the subject of the February 2012 edition of Destacamus, a bimonthly magazine published by Biopol’H which profiles researchers.
Last week, IBEC welcomed a group of third year E.S.O. students from the Oak House School in Barcelona, who were taking part in the ESCOLAB initiative of the City Council of Barcelona.
IBEC director and head of the Biomaterials for Regenerative Therapies group Josep Planell was quoted as an expert opinion last week in an article in La Vanguardia. The story covered a new chip developed at MIT able to release drugs under the skin while dosage and timing is controlled wirelessly.
This week’s 5th Annual Conference of the Biomedical Research Technology Platforms in Barcelona, which IBEC is attending in its capacity as coordinator of the Spanish Nanomedicine Platform (NanoMed Spain), is the subject of an article in Spanish healthcare magazine Redacción Médica today.
The two IBEC-led CIBER-BBN tissue regeneration projects that were earmarked for funding by the EU’s ERA-NET EuroNanoMed initiative last year (see www.ibecbarcelona.eu/IBEC-News/funding-success-for-two-ibec-projects.html) have both received the national support they need to get started.